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Abstract: Approximately 16 million people in the United States suffer from anxiety disorders 
alone, while another 12 million experience both anxiety and at least one other psychiatric 
condition. Generalized anxiety disorder (GAD) has lifetime prevalence rates between 5% and 
6%. Treatment of GAD is aimed primarily at symptom reduction. Duloxetine, a serotonin 
norepinephrine reuptake inhibitor (SNRI), received Food and Drug Administration (FDA) 
approval for the treatment of GAD in 2007. This article reviews the pharmacologic proﬁ  le and 
seminal clinical trials associated with the FDA indication of duloxetine for GAD. A literature 
search performed using PubMed with the keywords “duloxetine”, “gad”, “generalized anxiety 
disorder”, and “venlafaxine XR” yielded 27 articles. We also focused on papers that pooled 
data from these seminal studies. Data on ﬁ  le from Eli Lilly were also reviewed, including data 
from the Eli Lilly website. Based on this search, duloxetine was found to be an FDA-approved 
treatment option for GAD that has been studied in several double-blind, placebo-controlled 
clinical trials. This review of duloxetine will help physicians to interpret clinical studies properly 
and also help them to make an informed decision about which patients are the most appropriate 
candidates for a trial of duloxetine.
Keywords: duloxetine, generalized anxiety disorder, clinical trials, serotonin norepinephrine 
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Introduction
Anxiety disorders were classiﬁ  ed as neurotic disorders until the establishment of the 
DSM-III in 1980. Approximately 16 million people in the United States suffer from 
anxiety disorders alone, while another 12 million experience both anxiety and at least 
one other psychiatric disorder.1
Generalized anxiety disorder (GAD) involves excessive worry about everyday 
life events, on more days than not, for a period of at least 6 months.2 According to 
DSM-IV-TR, patients must ﬁ  nd it “difﬁ  cult to control the worry” and must present with 
3 of the following 6 criteria: restlessness or feeling keyed up, being easily fatigued, 
difﬁ  culty concentrating or mind going blank, irritability, muscle tension, or sleep 
disturbance.2 Patients with GAD often present hyper-vigilant, with somatic complaints 
such as musculoskeletal pain or gastrointestinal disturbance.3 GAD has lifetime 
prevalence rates between 5% and 6%, and a male to female ratio of 1:2.4
Treatment of GAD is aimed at symptom reduction, often utilizing selective 
serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors 
(SNRIs), buspirone, benzodiazepines and/or psychotherapy. In 1991, Butler et al 
published evidence supporting the use of cognitive behavioral therapy (CBT) in 
the treatment of GAD.5 Both venlafaxine and duloxetine have been Food and Drug 
Administration (FDA) approved for the treatment of GAD.
Another SNRI, milnacipran, is not yet available in the United States, but is utilized 
clinically to treat major depressive disorder (MDD) and chronic pain in other parts of 
the world including Europe.6 Duloxetine, an SNRI, received FDA approval for MDD Neuropsychiatric Disease and Treatment 2009:5 24
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and Diabetic peripheral neuropathic pain (DPNP) in 2004.7 
Preclinical studies of duloxetine indicated an anxiolytic effect 
based on reduction in animal anxiety behaviors.7,8 Finally, 
duloxetine received FDA approval for the treatment of GAD 
in February of 2007.7 According to Eli Lilly (the manufac-
turer of duloxetine), GAD patients treated with duloxetine 
in clinical trials showed a 46% improvement in anxiety 
symptoms when compared with placebo.8
This article will review the pharmacologic proﬁ  le and 
seminal clinical trials associated with the FDA indication of 
duloxetine for GAD. Conﬁ  dence in the predictability of safety, 
tolerability and efﬁ  cacy of a medication is directly proportional 
to the magnitude and quality of its published trials. The goal 
of this paper is to assess the amount of information from well-
controlled systematic trials. This information forms the basis 
for evidence-based medical practice and helps clinicians to 
make the most appropriate decisions.
Materials and methods
A literature search was performed using PubMed with keywords 
“duloxetine,” “gad,” “generalized anxiety disorder,” and 
“venlafaxine XR.” The search yielded 27 articles. We included 
large, multi-center studies and focused on the seminal papers that 
led to the FDA approval for duloxetine in GAD. We also focused 
on papers that pooled data from these seminal studies.
Data on ﬁ  le from Eli Lilly was also reviewed, including 
data from the Eli Lilly website. We also included information 
available in the duloxetine package insert, as well as the 
Physicians Desk Reference (PDR).
Before we examine data on the efﬁ  cacy of duloxetine as 
a treatment for GAD, we review the basic pharmacology of 
duloxetine.
Pharmacodynamics of duloxetine
The ratio of duloxetine`s afﬁ  nity constants for serotonin (5HT) 
and norepinephrine (NE) reuptake pumps is closer to 1, meaning 
it is a more balanced and potent inhibitor for these two reuptake 
pumps than venlafaxine.9 Duloxetine has a Ki of 0.8 nM for 
NE and 7.5 nM for 5HT, whereas venlafaxine’s Ki for NE and 
5HT are 2480 nM and 82 nM respectively.9 Hence, duloxetine 
has greater afﬁ  nity for both 5HT and NE.10 Like venlafaxine 
and milnacipran, duloxetine has minimal afﬁ  nity for dopamine, 
histamine (H1), adrenergic, muscurinic, opiate, gamma amino 
butyric acid (GABA), and substance P receptors.9
Pharmacokinetics of duloxetine
Compared with most antidepressants, duloxetine exhibits 
some unusual absorption properties. Duloxetine is rapidly 
hydrolyzed in acidic media to naphthol, which has no 
antidepressant activity.10 To overcome this issue, the pellets 
inside the duloxetine capsule are enteric coated, but the capsule 
is not. This enteric coating of the pellets resists dissolution 
until pellets reach a segment of the gastrointestinal tract where 
the pH is favorable. This explains why the maximal plasma 
concentration (Cmax) of duloxetine usually does not occur until 
6 hours post dose.10
Duloxetine has a mean plasma half-life of 12 hours, but 
it can be dosed once daily as the central nervous system 
half-life may be very different from the plasma half-life. 
In one reported study, duloxetine dosed at 20 to 40 mg 
twice daily in 12 healthy male volunteers exhibited linear 
pharmacokinetics with steady state plasma concentrations 
typically reached within 3 days of stable dosing.9 Duloxetine 
is highly protein bound (96%), primarily to albumin and 
alpha-1-acid glycoprotein.10
Duloxetine is metabolized by CYP-2D6 and 1A2 isoenzymes 
with no active metabolites.10 Because of CYP-1A2 metabolism, 
duloxetine use in smokers results in a one third reduction in 
bioavailability compared with non-smokers.10 However, there 
is no clinical recommendation for a dosage adjustment based on 
smoking status.10 Duloxetine should not be used with CYP-1A2 
inhibitors such as ﬂ  uvoxamine.9
Based on in vitro studies, duloxetine is a more potent 
inhibitor of CYP 2D6 than CYP 1A2. Concomitant use 
of duloxetine at a dose of 120 mg/day increased levels 
of desipramine 3-fold, a model CYP 2D6 substrate, 
indicating substantial inhibition of CYP 2D6.11 However, 
the recommended dose of duloxetine for the treatment of 
MDD is 40 to 60 mg/day. At these recommended doses, 
the increase in plasma levels of CYP 2D6 substrates drugs 
like desipramine would be expected to be one third to one 
half that seen with the 120 mg/day dose (ie, 1 to 1.5 fold 
increase). This is consistent with the linear pharmacokinetics 
of duloxetine over this dose range, meaning it has no effect 
on its own CYP 2D6 mediated clearance.11 The effect of 
duloxetine on CYP 2D6 is signiﬁ  cantly less than as seen 
with fluoxetine or paroxetine at their lowest effective 
antidepressant doses and approximately the same as seen 
with escitalopram and citalopram.9 Thus duloxetine should 
be used with caution when combined with potent inhibitors 
of CYP-2D6 such as paroxetine and drugs using CYP 2D6 
for their own clearance, particularly those with narrow 
therapeutic indexes, as signiﬁ  cantly high concentrations of 
duloxetine may result.10
Duloxetine is excreted in urine (70%) and feces (20%), 
with less than 1% excreted unchanged (urine).12Neuropsychiatric Disease and Treatment 2009:5 25
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Dosing
Clinical trials studying the efﬁ  cacy of duloxetine in the 
treatment of GAD utilized doses ranging from 60 mg to 
120 mg daily.3,13,14 Duloxetine is available in capsules 
of 20 mg, 30 mg, and 60 mg strengths. According to the 
manufacturer, the recommended dose of duloxetine in 
GAD is 60 mg/day.7 The manufacturer states: “There is no 
evidence that doses greater than 60 mg/day confers additional 
beneﬁ  t, while adverse reactions such as dizziness, fatigue, 
somnolence, constipation, and decreased appetite were 
observed to be dose-dependent.”7
Safety
Pooled data from clinical trials involved four cases of over-
dose ingesting up to 1400 mg of duloxetine, with no reported 
fatalities. For the purposes of the studies, overdose was 
deﬁ  ned as dose  240 mg. Cardiovascular adverse events 
and toxicity in overdose associated with venlafaxine do not 
seem to be a concern with duloxetine.14
Duloxetine is not recommended for patients with end stage 
renal disease (ESRD), because following a single dose of 60 
mg of duloxetine, the elimination half-life remains the same, 
but the Cmax and AUC (area under the curve used to estimate 
bioavailability) values are approximately 100% greater 
compared with individuals with normal renal function.15
Because hepatic insufficiency impairs duloxetine 
metabolism, some researchers have suggested that such 
patients not be prescribed duloxetine.13 After a single dose 
of 20 mg, the half-life of duloxetine was 3 times longer, the 
mean AUC was 5 times greater, and the plasma clearance was 
6 to 7 times less in 6 cirrhotic patients with moderate liver 
impairment versus what was seen in age and gender matched 
healthy controls.9
Preclinical studies demonstrated the potential for 
substantial central pharmacodynamic drug-drug interactions 
when duloxetine as well as other 5HT and NE uptake 
inhibitors are coadministered with drugs having speciﬁ  c 
effects on central 5HT, NE, and DA mechanisms.9 Such 
5HT and NE reuptake pump inhibitors include tertiary and 
secondary amine tricyclic antidepressants (TCAs), selective 
5HT uptake inhibitors (SSRIs), selective NE uptake pump 
inhibitors (eg, reboxetine), and other dual 5HT and NE uptake 
pump inhibitors (eg, venlafaxine and milnacipran). For simi-
lar reasons, the duloxetine package insert includes a warning 
against using duloxetine in combination with monoamine 
oxidase inhibitors (MAOIs).7 Such a combination has the 
potential to cause both a serotonin syndrome, as can occur 
with simultaneous administration of an SSRI and a MAOI, 
and a hypertensive crisis, as can occur with the combined 
administration of an selective NE reuptake pump inhibitor 
(eg, desipramine or reboxetine) and a MAOI.7
Duloxetine is currently pregnancy category C and possible 
effects on labor, delivery, and a developing fetus are unknown 
at this time.10 Use of duloxetine during pregnancy should be 
supervised by an expert, only after careful assessment of risk, 
patient education, and informed consent.10
Data from 4 randomized, double-blind, placebo controlled 
trials of duloxetine in patients  65 years of age showed it 
to be a safe treatment modality in elderly with GAD. The 
study showed a high rate of discontinuation (22.2%) due to 
adverse effects.16
Adverse effects
Patients should be made aware of the risks, beneﬁ  ts, possible 
side effects and alternatives associated with any medication 
prior to treatment. Pooled data from 3 clinical trials revealed a 
16% discontinuation rate for patients treated with duloxetine 
compared with only 4% for placebo.8 The venlafaxine 
comparator arm of one study showed only an 11% discontinu-
ation rate, which was lower than the 23% discontinuation rate 
shown in previous pooled data.14 The most common adverse 
effects included nausea, fatigue, dry mouth, somnolence, 
vomiting, insomnia, and sexual side effects.8
Side effects commonly associated with duloxetine are 
similar to those seen with venlafaxine or SSRIs. Nausea and 
insomnia are common side effects of duloxetine, although 
nausea seems to be less common than with SSRIs. After the 
ﬁ  rst week of treatment, nausea rates associated with duloxetine 
are comparable to placebo.13 PDR indicates a nausea rate of 
31% with venlafaxine, compared to 22% with duloxetine, at 
75 to 225 mg and 40 to 120 mg respectively.12
Eight- to nine-week clinical trials studying duloxetine 
use in depression resulted in a 1.1 lb (1 lb = 0.45 kg) weight 
loss in the treatment group compared to a 0.5 lb weight gain 
in the placebo group.3,13,14 One year follow-up data showed 
a weight gain of 2.46 lb for patients in the treatment group, 
but no placebo group data were available.10
Clinical trial data showed clinically insigniﬁ  cant elevations 
in liver function tests in some patients, with most experts 
recommending that duloxetine not be used in those with a history 
of severe liver abnormalities. On follow-up, abnormalities in 
liver function tests were noted to decrease, regardless of 
whether or not the patient stopped using duloxetine.3
Sexual side effects were measured prospectively utilizing 
the Arizona Sexual Experience Scale (ASEX). Short-term 
clinical trials showed statistically signiﬁ  cant sexual side Neuropsychiatric Disease and Treatment 2009:5 26
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effects for duloxetine when compared to placebo (p = 0.007). 
Male anorgasmia was the main effect noted. However, after 6 
months the treatment group showed no statistically signiﬁ  cant 
increase in sexual side effects compared with the placebo 
group (p = 0.677).17
Urinary retention or hesitancy was rarely reported in 
clinical trials. Less than 2% of patients encountered this 
side effect, and no patient was catheterized.18 Clinical trials 
showed no evidence of QT prolongation, effect on glucose 
metabolism, hematologic abnormalities or difﬁ  culties with 
other organ systems.13
There were no reported cases of mania in patients taking 
duloxetine, compared with 2% of placebo controls. As with 
SSRIs and venlafaxine, patients taking duloxetine should 
be carefully monitored for treatment-emergent mania. 
Concomitant use of a mood-stabilizing medication should 
be considered in such cases.10
Sudden discontinuation can result in withdrawal 
symptoms, including but not limited to dizziness, anxiety, 
nausea, and headache. Because of possible discontinuation 
syndrome, duloxetine should be tapered rather than stopped 
abruptly.14 Patients should be made aware of the discontinue 
syndrome at the start of treatment with duloxetine.
However, the above clinical trials showed that “discontinu-
ation-emergent adverse events” for duloxetine were statistically 
significant comparable to placebo.13,14 The venlafaxine 
comparator arm of study 3 also showed statistically signiﬁ  cant 
“discontinuation-emergent adverse events” compared with 
placebo.14
In May of 2007 the FDA expanded its black box warning 
regarding antidepressant medication and suicidality to 
include young adults aged 18 to 24 years. A case series by 
Parikh et al showed a close relationship between suicidality 
and duloxetine use. In the cases presented, suicidal ideation 
was linked to an increase in duloxetine dose.19 In all cases 
presented, patients were no longer suicidal upon discontinu-
ation of duloxetine. All patients prescribed antidepressant 
medication should provide appropriate informed consent on 
the risk of suicidality prior to the start of treatment.
Having reviewed the basic pharmacology and safety data 
on duloxetine, we will now look at the bedrock studies that 
led to FDA approval for the treatment of GAD.
Efﬁ  cacy in GAD
We will discuss data from clinical trials that were designed 
to assess the efﬁ  cacy of duloxetine in treating patient’s 
meeting DSM-IV-TR criteria for GAD.3,13,14 Each study 
utilized the Hamilton Rating Scale for Anxiety (HAM-A) 
score as the primary efﬁ  cacy measure. Secondary efﬁ  cacy 
measures included HAM-A items for tension and anxious 
mood, HAM-A Psychic and Somatic Factors, Hospital 
Anxiety and Depression Scale (HADS), Clinical Global 
Impressions Improvement scale (CGI-I) scores, and Patient 
Global Impression-Improvement Scale (PGI-I).3,13,14
The ﬁ  rst study was a 9-week, double-blind, placebo 
controlled trial of 513 patients meeting DSM-IV-TR criteria 
for GAD.3 Inclusion criteria included age   18 years, and 
a primary diagnosis of GAD as obtained using the Mini 
Neuropsychiatric Interview for DSM-IV-TR.3 Patients were 
recruited from 42 outpatient treatment centers in 7 countries 
including the United States and parts of Europe. The mean 
age of study participants was 43.8 years of age, with 67.8% 
females.3
Patients were screened including medical history 
and physical examination with EKG, renal function 
tests, thyroid function tests, and urine drug screens. 
Patients were required to score at least 4 on the Clincical 
Global Impressions-Severity of Illness scale (CGI-SI). 
Patients were also required to score at least 10 on the 
Hospital Anxiety and Depression (HAD) anxiety subscale 
and at least 9 on the COVI anxiety scale.3
Unlike previous efﬁ  cacy studies involving venlafaxine, 
the patients were evaluated using the HAM-A, but were not 
selected based on a minimum HAM-A score. Patients were 
also evaluated using the Sheehan Disability Scale (SDS). 
Response, remission and sustained improvement rates were 
also documented.3
Exclusion criteria for the study included a diagnosis of 
MDD (patients could not score   3 on any item of the Raskin 
Depression Scale) or substance use disorder within the past 
six months. Exclusion criteria also included a past year diag-
nosis of post-traumatic stress disorder, panic disorder, eating 
disorder, any prior history of a psychotic disorder, obsessive 
compulsive disorder, and bipolar disorder. Patients under-
going psychotherapy within 6 weeks of the study were also 
excluded from participation in the study.3 Patients were also 
excluded if they underwent 2 previous unresponsive trials 
of antidepressant or benzodiazepine medication for GAD. 
Patients were required to be free of all psychotropic medi-
cations for 2 to 4 weeks prior to randomization, depending 
on the psychotropic medication in question.3 Altogether 
126 patients were excluded from the study based on these 
criteria.3
All patients received single-blinded placebo treatment 
for 1 week before being randomized to receive placebo, 
60 mg/day of duloxetine, or 120 mg/day of duloxetine. Neuropsychiatric Disease and Treatment 2009:5 27
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A patient’s dose could be decreased to 30 mg/day of 
duloxetine if they were unable to tolerate the starting dose. All 
patients who remained in the study were gradually increased 
to their randomly assigned dose over a two week period. The 
patients in the duloxetine groups were randomly assigned to 
either abrupt discontinuation or gradual (2 week) taper at the 
end of the study.3
The results of the first study yielded a statistically 
signiﬁ  cant (p   0.001) improvement in HAM-A scores 
with duloxetine when compared to placebo (see Table 1). At 
60 mg/day of duloxetine the mean decrease in HAM-A score 
was 12.8 compared with only 8.4 for placebo. At 120 mg/day 
the mean decrease in HAM-A score was 12.5.3
Response was deﬁ  ned as  50% reduction in HAM-A at 
treatment endpoint. Sustained improvement was deﬁ  ned as a 
30% reduction in HAM-A that was sustained at all subsequent 
visits. Remission was deﬁ  ned as a HAMA total score   7 at 
completion of the study.3 Duloxetine demonstrated response 
rates of 58% at 60 mg/day and 56% at 120 mg/day compared 
to 31%, for placebo (p   0.001). Remission rates were 31% 
at 60 mg/day and 38% at 120 mg/day compared with 19% 
for placebo (p   0.01 and p   0.001 respectively). Sustained 
improvement rates were 63.6% at 60 mg/day and 66.9% at 
120 mg/day compared with 42.8% for placebo (p   0.001). 
Further, both duloxetine groups had greater improvements in 
Sheehan Disability Scale global scores (p   0.001), HAM-A 
psychic factor (p   0.001), and HAM-A somatic factor scores 
(p   0.01).3 Effect on overall disability will be discussed in 
more detail later.
The second and third studies were ﬂ  exible-dose trials, also 
using mean change in HAM-A score to assess efﬁ  cacy.13,14 
The third study also provided a comparison to venlafaxine 
XR.13,14
The second study was a 10 week multi-center, double-blind, 
placebo-controlled trial. The study randomized 327 patients 
meeting DSM-IV-TR criteria for GAD to a duloxetine treatment 
group or to placebo (Table 1). The duloxetine arm received 
60–120 mg of duloxetine with progressive titration and ﬂ  exible 
dosing.13 The study involved 27 outpatient treatment centers. 
Patients were screened using the same CGI-Severity of Illness 
and HAD criteria as the ﬁ  rst study. Patients were also required 
to score at least a 4 on the Covi Anxiety Scale.13 Exclusion 
criteria were essentially the same as the ﬁ  rst study with 188 
patients failing to meet the entry criteria.13
The study was single-blinded for the ﬁ  rst week with all 
patients receiving placebo. Starting in week 2, the study was 
double-blind and patients were randomly assigned to receive 
60 mg per day of duloxetine or placebo. Study visits were 
held at 1,2,4,7 and 10 weeks. A dosage decrease from 60 mg 
to 30 mg per day was allowed in the ﬁ  rst 2 weeks, with all 
patients in the duloxetine arm required to take the 60 mg dose 
by the end of the second week. The dose of duloxetine was 
increased if a patient’s CGI score was  3. The maximum 
dose was 120 mg/day. 62% of the original sample completed 
the ten week therapy.13
The third study utilized the same inclusion and exclusion 
criteria as the second study. Besides that, third study also 
excluded patients meeting criteria for any Axis II disorder 
or having history of antisocial behavior. In the third study 
patients were randomized to duloxetine (n = 162), venlafaxine 
(n = 164), or placebo groups (n = 161) (Table 1). Duloxetine 
was started at a dose of 30 mg per day for 1 week and was then 
increased to a range of 60 to 120 mg per day thereafter. The 
dosage increases for duloxetine followed the same algorithm 
as the second study following the second week of treatment, 
with a maximum dosage of 120 mg per day.14
Venlafaxine was utilized in the XR formulation and was 
started at 37.5 mg per day and increased to a dosage range of 
75 to 225 mg per day. According to Eli Lilly the study was 
not “powered to compare efﬁ  cacy between Cymbalta and 
Effexor XR.”8 Eli Lilly states that data from another study 
will be pooled with data from this study to provide a more 
statistically powerful head-to-head comparison of duloxetine 
and venlafaxine XR.8
Results of both study 2 and study 3 showed a statistically 
signiﬁ  cant decrease in HAM-A scores for the duloxetine 
Table 1 Efﬁ  cacy studies of duloxetine in the treatment of GAD
Study Number 
of subjects
Average 
age
Gender Study length Design Dosing Change in HAM-A Statistical 
signiﬁ  cance
Koponen et al3 513 43.8 67% ♀ 9 week Placebo-controlled Fixed ↓12.8 (60 mg/day) p   0.001
Rynn et al13 327 41.6 61.7% ♀ 10 week Placebo-controlled Flexible ↓8.12 p = 0.023
Hartford et al14 487a 40.4b 64.2%b ♀ 10 week Placebo-controlled Flexible ↓11.8 p   0.001
aduloxetine efﬁ  cacy study with venlafaxine XR comparator arm [duloxetine (n = 162), venlafaxine (n = 164), and placebo groups (n = 161)]
bduloxetine group.Neuropsychiatric Disease and Treatment 2009:5 28
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groups when compared to placebo (p = 0.023 for study 2 and 
p   0.01 for study 3).13,14
Secondary efficacy measures for study 2 showed 
statistically signiﬁ  cant improvement in HAM-A items for 
anxious mood (−0.98, p = 0.006), tension (−0.98, p = 0.014), 
fears (−0.49, p = 0.049), cognitive (−0.98,  0.001), depressed 
mood (−0.43, p = 0.003), and behavior (−0.66, p = 0.011) 
compared with placebo.13 In the second study the CGI-I 
endpoint (2.68) and PGI-I endpoint (2.88) also showed 
a statistically significant change with respect to pla-
cebo (p = 0.04 and p = 0.046 respectively).13 The HAM-A 
psychic factor scale also showed statistically signiﬁ  cant 
improvement (−5.33, p   0.001) compared with placebo 
in the second study.13 The HADS anxiety subscale (−3.92, 
p = 0.001) also showed a statistically signiﬁ  cant change when 
compared to placebo in the second study.13 The HAM-A 
somatic factor, insomnia, somatic muscular, somatic sensory, 
cardiovascular, respiratory, gastrointestinal, genitourinary, 
and autonomic items did not show a statistically signiﬁ  cant 
change when compared to placebo.13 The HADS depression 
subscale also did not show ﬁ  ndings that were statistically 
signiﬁ  cant.13
Secondary efficacy measures for study 3 showed 
signiﬁ  cant improvement when compared to placebo (in the 
duloxetine group) for the HAM-A psychic factor (−7.01), 
HAM-A anxious mood (–1.40), HAM-A tension (−1.37), 
CGI-I endpoint (2.39), PGI-I endpoint (2.60), HADS anxiety 
subscale (−6.22) and HADS depression subscale (−3.91).14
The above studies showed duloxetine to be an effective 
treatment for GAD. However, it is often difficult to 
extrapolate clinical trial data to “real world” patients 
encountered in clinical practice.
Tunis et al deﬁ  ned a practical clinical trial as “a study 
design that compares clinically important interventions, 
a diverse population of study participants representative 
of clinical practice, inclusion of a range of heterogeneous 
practice settings that are also representative of clinical 
practice, and measurement of a broad range of clinically 
relevant health outcomes.”20 Strengths of the above studies 
include use of standardized rating scales such as HAM-A in 
the evaluation of patients, large sample-size, multi-center, 
effective randomization, and double-blind design.
However, generalizability of research findings from 
clinical trials is a methodological concern. Because most of 
the studies exclude many participants with general medical 
and psychiatric co-morbidities, generalizability of the results 
is limited. The study also excluded patients with a history of 
previous unresponsiveness to SSRI or benzodiazepine in the 
treatment of GAD, therefore selecting out non-responders who 
may be encountered in clinical practice. Homogeneity between 
the sample population and the target population is necessary 
so that the results can be extrapolated. Other limitations of 
the above studies include a short time to evaluate treatment 
and response. Patients in clinical practice typically utilize 
antidepressant medications for longer than 9 to 10 weeks.
Results of long-term studies could provide information 
on remission rates that would be clinically useful. Long-term 
studies would also provide clinicians with information on 
maintenance treatment. Davidson, et al published results of 
a 26 week double-blind, placebo controlled, trials looking at 
efﬁ  cacy of duloxetine in relapse prevention. Study patients 
ﬁ  rst completed a 26-week, open-label, acute-therapy phase. 
Patients included in the study were those that responded to 
this acute phase treatment, deﬁ  ned as  50% reduction in 
Hamilton Anxiety Rating Scale and “much” to “very much” 
improved ratings for the last two visits of acute open label 
treatment. For study purposes, relapse was deﬁ  ned as  2 point 
increase in illness severity ratings or by discontinuation for 
lack of efﬁ  cacy. 41.8% of placebo-treated patients experienced 
relapse of their illness based on the above criteria, compared 
with only 13.7% of duloxetine treated patients (p   0.001) at 
the end of the second 26 weeks (continuation phase).21
Pollack, et al pooled data from three clinical trials (n = 688) 
and showed that 100% of responders to duloxetine ( 80% 
improvement of HAM-A) at week 2 and 93% of responders 
at week 4 were responders to treatment at endpoint. Similar 
data is not available for SSRI’s at this time, but would be 
helpful in evaluating treatment options clinically.22
We have now reviewed the efﬁ  cacy data that lead to FDA 
approval for treatment of GAD. Data from these studies was 
also pooled to examine improvement in quality of life.
Quality of life
In clinical practice, improvement of an individual’s qualify 
of life is a sought-after result that is difﬁ  cult to pull from 
research studies. A 2008 study by Pollack et al pooled data 
from 3 studies to assess if duloxetine improved quality of 
life in patients meeting DSM-IV-TR criteria for GAD.23 
By utilizing comparative norms, the analysis examined the 
clinical importance of the functional outcomes improvements 
reported in the above studies. Speciﬁ  cally, the study sought 
to examine how this data on functional outcomes would 
translate into real-world clinical improvement.23
Individual patient data was pooled from the above studies, 
with outcome criteria deﬁ  ned as above. At baseline, 89% of 
patients were impaired on the Sheehan Disability Scale (SDS) Neuropsychiatric Disease and Treatment 2009:5 29
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global functioning and 95% of patients were impaired on the 
Quality of Life Enjoyment and Satisfaction Questionnaire 
Short Form (Q-LES-Q-SF).23 The study confirmed the 
belief that patients with GAD have impaired functioning 
and quality of life. Following treatment, the duloxetine 
group showed statistically signiﬁ  cant improvement when 
compared to placebo (p   0.001).23 The mean SDS score for 
the duloxetine treatment groups at completion ranged from 
7.4 to 9.5 compared with a mean range of 11.4 to 12.1 for 
placebo-treated groups.23 47% of duloxetine treated patients 
achieved a normative SDS score at studies end, compared 
with 28% of placebo-treated patients (Figure 1).23
Duloxetine treated patients not only demonstrated improved 
quality of life, but improved overall satisfaction as studied by 
the Q-LES-Q-SF.4 Mean endpoint scores on the Q-LES-Q-SF 
ranged from 65.9% to 67.9% for the duloxetine group compared 
to 58.5% to 60.9% for the placebo group (Figure 1).23 Two of 
the three clinical trials demonstrated a signiﬁ  cant improvement 
of Q-LES-Q-SF compared with placebo. Duloxetine treated 
patients were not only able to better carry out role functioning, 
but were more satisﬁ  ed with their quality of life.24,25
Over 1100 patients were included in this analysis with the 
improvements in quality of life being replicated in all three. 
While such data is useful in real-world clinical practice, 
studies with longer follow-up would better determine 
long-term maintenance of such improvements.24
TCAs and venlafaxine are often utilized clinically 
in patients with concomitant chronic pain issues. The 
mechanism of action of duloxetine lends itself to similar use, 
and we will examine data in this regard.
Chronic pain
Duloxetine received FDA approval for the treatment of 
diabetic peripheral neuropathic pain in 2004 and is often 
utilized clinically in patients whose anxiety is marked by 
somatic symptoms or who have concomitant chronic pain. 
Pooled results from two studies showed that 44.4% of 
patients identiﬁ  ed with GAD had visual analog scale (VAS) 
scores   30.26
Hartford et al conducted a post hoc evaluation of two 
double-blind, placebo-controlled trials examining efﬁ  cacy 
of duloxetine in GAD. Duloxetine showed reduction in 
pain on all 6 VAS pain scales (p   0.001).27 Russell et al 
also pooled data from two double-blind, placebo-controlled 
trials looking at efﬁ  cacy of duloxetine in GAD. Results of 
this pooled analysis also showed that patients receiving 
duloxetine showed improvement on all 6 VAS pain scales 
(p   0.001 for overall pain, p = 0.009 for headache, p = 0.003 
for back pain, p   0.001 for shoulder pain, p   0.001 for 
daily interference due to pain, and p   0.001 for proportion 
of the day while awake with pain).26
As above this is of particular interest to clinicians because 
of the frequent overlap between pain and anxiety in GAD. 
Also, as further advances in neuroscience come to light, 
further structural and neurophysiologic links between pain 
and anxiety in GAD could be uncovered.
Now that we have evaluated data that is pertinent to 
clinical practice for duloxetine, we will take a brief look 
at the data for venlafaxine XR, another SNRI that is FDA 
approved for treatment of GAD.
Venlafaxine XR
While no head-to-head trials comparing duloxetine with 
other medications for the treatment of GAD currently 
exist, venlafaxine XR, an SNRI, was FDA approved for the 
treatment of GAD in 1991.
In 2000, a study published in the American Journal 
of Psychiatry examined the efﬁ  cacy of venlafaxine XR in 
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the treatment of non-depressed outpatients with GAD.28 
The study was an 8-week, double-blind, ﬁ  xed dose trial that 
randomized patients to placebo (n = 96) or venlafaxine XR.28 
Venlafaxine XR was dosed at 75 mg/day (n = 86), 150 mg/day 
(n = 81), or 225 mg/day (n = 86).28
Patients included in the study scored at least an 18 on the 
HAM-A and at least a 2 on the anxious mood and tension 
factors subscale. Unlike the above studies involving 
duloxetine, this study utilized HAM-A score as part of the 
inclusions criteria. Primary efficacy measures included 
change in total HAM-A score (Table 2).
In 2000, results of a 6-month, double blind, placebo-controlled 
trial showed long-term effectiveness in the use of venlafaxine 
XR to treat GAD.29 The study was a 28-week, double-blind, 
placebo-controlled, ﬂ  exible dose trial involving 251 non-
depressed adult outpatients meeting DSM-IV criteria for 
GAD (Table 2).29
The goal of this article is not to compare venlafaxine XR 
to duloxetine for the treatment of GAD. However, clinicians 
may often need to choose between these two medications as 
an initial therapy or as an option for patients who have failed 
a trial of a different medication.
The two studies that we discussed on venlafaxine XR 
used HAM-A score as an entry criteria for the study, while 
the studies we discussed on duloxetine did not. By not 
using HAM-A score as an entry criteria, the duloxetine 
study designs may have reduced the potential for rater 
bias.14
An additional study comparing venlafaxine XR with 
duloxetine will generate data that will be pooled with the 
Hartford study to provide a better powered comparison of 
the two agents.14
At this time venlafaxine XR and duloxetine are both 
safe and efﬁ  cacious treatment options for clinicians to 
consider in GAD. Similar to our discussion of duloxetine 
as a possibility for patients with somatic manifestations of 
anxiety, choosing venlafaxine XR may often be based on 
co-morbidities. Additional studies in this area could also be 
useful to clinicians.
Future studies
An NIMH sponsored trial (NCT00183274) is currently 
recruiting subjects to study “Effectiveness of Long-Term Ver-
sus Short-Term Treatment of Generalized Anxiety Disorder 
With Venlafaxine XR.”30 The National Taiwan Hospital 
(NCT00491348) is currently recruiting subjects to study 
“Effects of Duloxetine on Pathological Worry in Patients with 
Generalized Anxiety Disorder: A fMRI Study.”30
Conclusion
Duloxetine is an FDA approved treatment option for GAD 
that has been studied in acute phase 9- to 10-week double-
blind, placebo-controlled clinical trials. Duloxetine has also 
been evaluated for relapse prevention (26-week continuation) 
in patients whose GAD symptoms have responded 
after 26 weeks of acute phase treatment. Duloxetine may also 
be particularly useful to clinicians treating GAD patients with 
concomitant chronic pain or who have signiﬁ  cant somatic 
symptoms as a part of their anxiety.
The information presented is important because it forms 
the basis for the size and quality of the systematic database 
upon which physicians can form evidence based opinions 
about the reliability, safety, tolerability and efﬁ  cacy of 
duloxetine in patients with GAD. This article will help 
physicians to interpret clinical studies properly and apply that 
knowledge to their patients. As the evidence base with regard 
to maintenance therapy and treatment of speciﬁ  c symptoms 
of GAD grows, clinicians will be able to make an informed 
decision about which patients are the most appropriate can-
didates for a trial of duloxetine.
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Table 2 Efﬁ  cacy studies of venlafaxine XR in the treatment of GAD
Study Number
of subjects
Average age Gender Study length Design Dosing Change in HAM-A Statistical 
signiﬁ  cance
Rickels et al28 349 39.6a 56%a ♀ 8 weeks Placebo-controlled Fixed ↓12.36 (150 mg/day) p = 0.07
Gelenberg et al29 251 41** 68%b ♀ 6 months Placebo-controlled Flexible ↓13.4 p   0.001
Hartford et al14 487c 40.1b 62.2%b ♀ 10 weeks Placebo-controlled Flexible ↓12.4 p   0.01
*venlafaxine group randomized to 150 mg/day.
bvenlafaxine group.
cduloxetine efﬁ  cacy study with venlafaxine XR comparator arm [duloxetine (n = 162), venlafaxine (n = 164), and placebo groups (n = 161)].Neuropsychiatric Disease and Treatment 2009:5 31
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